Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Tafasitamab + Lenalidomide + Rituximab in Elderly Frontline DLBCL
2020-004977-38Phase 2Active
- Sponsor
- LYSARC
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab, lenalidomide and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by LYSARC. Primary endpoint: Overall metabolic response rate after 3 cycles or at treatment discontinuation. Started Apr 2021; status: active.
02
Drugs
tafasitamablenalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2020-004977-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004977-38.